AMP945 Improves Survival in Human Pancreatic Cancer Model
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
- Amplia Completes Manufacture of AMP945 for Planned Trials
- Amplia Provides Updated Investor Presentation
- Entitlement Offer Completed
- Amplia Awarded $2.1M R&D Cash Flow Loan
Later from Amplia Therapeutics
- Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
- Quarterly Activities and Cashflow Reports - March 2022 Qtr
- AMP945 Pre-IND Meeting Outcome
- Amplia Receives Second Ethics Clearance for Phase 2 Trial
- Preliminary Final Report and Annual Report YE 31 March 2022
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics